Summary of recent studies reporting disease outcomes in patients who discontinue TKI while in MMR or deeper
| Study . | N (patients, pregnancies) . | TKI therapy prior to stop, n (%) . | Time on TKI in months, median (range) . | ≥MMR at time of stopping TKI, n (%) . | Loss of MMR, n (%) . | ≥MMR recovery after TKI restart in those who lost MMR, n (%) . |
|---|---|---|---|---|---|---|
| Caldwell et al40 | 28, 38 | ND | ND | 29 (76) | 20 (69) | 18 (90)a |
| Chelysheva et al41 | 87, 87 | ND | ND | 87 (100) | 6 mo—57% 12 mo—66% | 6 mo—50% 12 mo—75% |
| Lee et al44 | 39, 50 | Imatinib 24 (48) Dasatinib 14 (28) Nilotinib 10 (20) Bosutinib 1 (2) Radotinib 1 (2) | 77 (6-194) | 44 (88) | 20 (45.5) | ND |
| Lasica et al42 | 16, 27 | Imatinib 13 (81) Dasatinib 2 (13) Nilotinib 1 (6) | 32 (3-84) | 12 (75) | 11 (92) | 12 (100) |
| Dou et al43 | 17, 17 | Imatinib 13 (76) Nilotinib 4 (24) | 49 (6-102) | 17 (100) | 10 (59) | 10 (100) |
| aThe remaining 2 patients were too early for evaluation. | ||||||
| ND , no data. | ||||||
| Study . | N (patients, pregnancies) . | TKI therapy prior to stop, n (%) . | Time on TKI in months, median (range) . | ≥MMR at time of stopping TKI, n (%) . | Loss of MMR, n (%) . | ≥MMR recovery after TKI restart in those who lost MMR, n (%) . |
|---|---|---|---|---|---|---|
| Caldwell et al40 | 28, 38 | ND | ND | 29 (76) | 20 (69) | 18 (90)a |
| Chelysheva et al41 | 87, 87 | ND | ND | 87 (100) | 6 mo—57% 12 mo—66% | 6 mo—50% 12 mo—75% |
| Lee et al44 | 39, 50 | Imatinib 24 (48) Dasatinib 14 (28) Nilotinib 10 (20) Bosutinib 1 (2) Radotinib 1 (2) | 77 (6-194) | 44 (88) | 20 (45.5) | ND |
| Lasica et al42 | 16, 27 | Imatinib 13 (81) Dasatinib 2 (13) Nilotinib 1 (6) | 32 (3-84) | 12 (75) | 11 (92) | 12 (100) |
| Dou et al43 | 17, 17 | Imatinib 13 (76) Nilotinib 4 (24) | 49 (6-102) | 17 (100) | 10 (59) | 10 (100) |
| aThe remaining 2 patients were too early for evaluation. | ||||||
| ND , no data. | ||||||